Guardant Health (GH) Stock Forecast & Price Target

$23.73

-0.60 (-2.47%)

(As of 09/6/2024 ET)

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 18 Analyst Ratings

Based on 18 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 1 has given a hold rating, and 17 have given a buy rating for GH.

Consensus Price Target

$39.31
65.67% Upside

High Forecast	$50.00
Average Forecast	$39.31
Low Forecast	$27.00

According to the 18 analysts' twelve-month price targets for Guardant Health, the average price target is $39.31. The highest price target for GH is $50.00, while the lowest price target for GH is $27.00. The average price target represents a forecasted upside of 65.67% from the current price of $23.73.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$39.31	$39.00	$36.91	$56.87
Forecasted Upside	65.67% Upside	38.10% Upside	58.24% Upside	82.56% Upside

Get Guardant Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

Ad Golden Crest

Biden’s Capital Gains Tax to Devastate Savings!

Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.

>> Get Your FREE Wealth Protection Guide <<

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Guardant Health Stock vs. The Competition

Type	Guardant Health	Medical Companies	S&P 500
Consensus Rating Score	2.94	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	65.67% Upside	1,206.56% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/21/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$32.00 ➝ $40.00	+42.30%
8/13/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$30.00 ➝ $34.00	+11.73%
8/8/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+48.27%
8/8/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$41.00 ➝ $42.00	+38.61%
8/8/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$45.00 ➝ $48.00	+58.00%
8/8/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $37.00	+21.79%
Get the Latest News and Ratings for GH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.
7/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $50.00	+37.51%
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $40.00	+22.89%
7/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $32.00	-1.33%
6/28/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$36.00	+23.92%
6/4/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$30.00 ➝ $38.00	+38.13%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$32.00	+17.09%
5/24/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$44.00 ➝ $44.00	+79.01%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
11/13/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$27.00	+25.12%
11/8/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$55.00 ➝ $50.00	+111.24%
9/28/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$34.00	+23.10%
9/8/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$60.00 ➝ $55.00	+129.26%
2/24/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$70.00 ➝ $53.00	+104.95%
1/4/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Outperform	$36.00	+34.83%
11/4/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$110.00 ➝ $83.00	+84.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:59 PM ET.

GH Forecast - Frequently Asked Questions

What is Guardant Health's forecast for 2024?: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $39.31, with a high forecast of $50.00 and a low forecast of $27.00.
Should I buy or sell Guardant Health stock right now?: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There is currently 1 hold rating and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GH shares.
Does Guardant Health's stock price have much upside?: According to analysts, Guardant Health's stock has a predicted upside of 35.96% based on their 12-month stock forecasts.
Has Guardant Health been upgraded by Wall Street analysts recently?: Over the previous 90 days, Guardant Health's stock had 1 upgrade by analysts.
What analysts cover Guardant Health?: Guardant Health has been rated by research analysts at Bank of America, BTIG Research, Citigroup, Craig Hallum, Guggenheim, JPMorgan Chase & Co., Piper Sandler, TD Cowen, The Goldman Sachs Group, and UBS Group in the past 90 days.
Do Wall Street analysts like Guardant Health more than its competitors?: Analysts like Guardant Health more than other "medical" companies. The consensus rating score for Guardant Health is 2.94 while the average consensus rating score for "medical" companies is 2.77. Learn more on how GH compares to other companies.